Distinguished in Gliosarcoma

Dr. Behnam B. Badie

Neurosurgery
City Of Hope Medical Foundation
1500 E Duarte Rd, 
Duarte, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Gliosarcoma
City Of Hope Medical Foundation
1500 E Duarte Rd, 
Duarte, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Behnam Badie is a Neurosurgery provider in Duarte, California. Dr. Badie is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, Awake Craniotomy, and Gastrostomy.

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurosurgery
Licenses
Neurological Surgery in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

CITY OF HOPE MEDICAL FOUNDATION
1500 E Duarte Rd, Duarte, CA 91010
Other Locations
CITY OF HOPE MEDICAL FOUNDATION
1500 Duarte Rd, Duarte, CA 91010
CITY OF HOPE MEDICAL FOUNDATION
209 Fair Oaks Ave, South Pasadena, CA 91030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent Glioblastoma
A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent Glioblastoma
Enrollment Status: Recruiting
Publish Date: July 10, 2025
Intervention Type: Other, Biological
Study Drugs: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive Glioblastoma
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Biological
Study Drug: Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes
Study Phase: Phase 1
Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma
Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Biological, Procedure
Study Drugs: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
Study Phase: Phase 1
Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma
Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2025
Intervention Type: Biological, Other, Procedure
Study Drug: HER2(EQ)BB?/CD19t+ T cells
Study Phase: Phase 1
View 3 Less Clinical Trials

67 Total Publications

Towards a Steerable Neurosurgical Robot for Debulking of Brain Mass Lesions.
Towards a Steerable Neurosurgical Robot for Debulking of Brain Mass Lesions.
Journal: IEEE robotics and automation letters
Published: July 21, 2025
Similar Doctors
Distinguished in Gliosarcoma
Dr. Christopher M. Duma
Neurosurgery
Distinguished in Gliosarcoma
Dr. Christopher M. Duma
Neurosurgery

Brain And Spine Surgeons Of Orange County A Medical Corporation

3900 W Coast Hwy, Suite 300, 
Newport Beach, CA 
 (35.1 miles away)
949-642-6787
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christopher Duma is a Neurosurgery provider in Newport Beach, California. Dr. Duma is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, Awake Craniotomy, and Deep Brain Stimulation.

Distinguished in Gliosarcoma
Dr. Linda M. Liau
Neurosurgery | General Surgery
Distinguished in Gliosarcoma
Dr. Linda M. Liau
Neurosurgery | General Surgery

The Regents Of The University Of California

757 Westwood Plz, 
Los Angeles, CA 
 (27.4 miles away)
Languages Spoken:
English
See accepted insurances

Linda Liau is a Neurosurgery specialist and a General Surgeon in Los Angeles, California. Dr. Liau is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. Her top areas of expertise are Astrocytoma, Glioma, Gliomatosis Cerebri, Glioblastoma, and Awake Craniotomy.

Distinguished in Gliosarcoma
Dr. John S. Yu
Neurosurgery
Distinguished in Gliosarcoma
Dr. John S. Yu
Neurosurgery

Cedars-Sinai Medical Center

8700 Beverly Blvd, 
West Hollywood, CA 
 (23.6 miles away)
310-423-5000
Languages Spoken:
English
See accepted insurances

John Yu is a Neurosurgery provider in West Hollywood, California. Dr. Yu is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Meningioma, Awake Craniotomy, and Gamma Knife Radiosurgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Badie's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 11 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile